Application of a Risk Score to Identify Older Adults with Community‐Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy

Abstract

To assess the impact of empiric Pseudomonas pharmacotherapy on 30‐day mortality in hospitalized patients with community‐onset pneumonia stratified according to their risk (low, medium, or high) of drug‐resistant pathogens.